CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients

Nicolas Picard$^{1,2,3,*}$, Koukeb Rouguieg-Malki$^{1,2,*}$, Nassim Kamar$^4$, Lionel Rostaing$^4$ and Pierre Marquet$^{1,2,3}$

$^1$INSERM UMR S-850, Limoges, France; $^2$Univ Limoges, Faculty of Medicine, Laboratory of Medical Pharmacology, Limoges, France; $^3$CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France; $^4$CHU Toulouse Rangueil, Department of Nephrology, Dialysis and Organ Transplantation, Toulouse, France.

Key words: everolimus; pharmacogenetics; pharmacokinetics; drug metabolism.

Word count: abstract: 179; text: 2167.

2 Tables; 2 figures.

Address for correspondence:

Dr. Nicolas PICARD,
Faculté de Médecine, Pharmacologie Médicale,
2 rue du Dr Marcland, 87025 Limoges, France
Tel: +33 555 435970; fax: +33 555 435936
Email. nicolas.picard@unilim.fr
Footnotes

The authors declare no conflict of interest.

N.P. and K.R-M. contributed equally to this work: N.P. supervised the experimental research and participated in data analysis and writing the manuscript; K.R-M. conducted the experimental research and participated in data analysis and writing the manuscript; N.K. and L.R. participated in clinical research design, patients enrolment and data collection; P.M. participated in research design and performance and critical review of the manuscript.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLint</td>
<td>intrinsic clearance</td>
</tr>
<tr>
<td>HLM</td>
<td>Human Liver Microsomes</td>
</tr>
<tr>
<td>P450</td>
<td>cytochromes P450</td>
</tr>
<tr>
<td>RAF</td>
<td>relative activity factor</td>
</tr>
<tr>
<td>rhCYP</td>
<td>recombinant human CYP</td>
</tr>
</tbody>
</table>
Abstract

Background. CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics.

Methods. We investigated the effect of CYP3A5 A6986G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients as well as on its in vitro hepatic metabolism using a bank of genotyped human liver microsomes (n=49). We further evaluated in vitro the contribution of CYP3A4, CYP3A5 and CYP2C8 to everolimus hepatic metabolism using recombinant enzymes.

Results. We found no association between CYP3A5 polymorphism and everolimus pharmacokinetics in renal transplant patients. On the other hand, no effect of CYP3A5 polymorphism was observed on the CL_int of everolimus by human liver microsomes, while that of tacrolimus (positive control) was 1.5-fold higher in microsomes carrying the CYP3A5*1 allele than in non-carriers. In vitro data showed that CYP3A4 is a better catalyst of everolimus metabolism than CYP3A5, while the opposite was observed for tacrolimus.

Conclusions. This study provides direct and indirect evidence that CYP3A5 genotyping cannot help improve everolimus therapy.
Introduction

Everolimus (Certican®, 40-O-(2-hydroxyethyl)—rapamycin) is a potent immunosuppressive drug used for the prevention of acute and chronic rejection after solid organ transplantation. It is a derivative of sirolimus (rapamycin). Because of the introduction of the 40-O-(2-hydroxyethyl) group, everolimus is more hydrophilic, has a shorter half-life and a relatively higher bioavailability compared to sirolimus (1). Everolimus and sirolimus are metabolized in the liver and in the gut wall primarily by the cytochrome P450 (P450) 3A enzymes and to a minor extent by CYP2C8 (2). CYP3A5 is highly polymorphic. The CYP3A5*3 allele results in a splicing defect, leading to a truncated protein with no enzyme activity; CYP3A5*1 is the wild-type allele, associated with enzyme activity. A large number of studies have investigated the influence of CYP3A5 polymorphism on the dose requirement and clearance of the immunosuppressant substrates of CYP3A. The CYP3A5*3 genotype appears to have a sufficiently large influence on tacrolimus metabolism to be used to guide drug dosing (3, 4). A similar association between the CYP3A5*3 genotype and dose requirement has been found for sirolimus, but not in all studies and only in patients not treated with a calcineurin inhibitor (5-7). The influence of this polymorphism on everolimus pharmacokinetics remains however unclear, as only one such study has been reported, showing no association between CYP3A5 genotype and everolimus blood levels or dose requirement in 30 adult cardiac transplants (8). In the present study, we investigated the impact of the CYP3A5*3 polymorphism on everolimus pharmacokinetics in 28 renal transplant patients receiving everolimus with no associated calcineurin inhibitor. In order to provide confirmation data, we studied the respective roles of CYP3A4 and CYP3A5 and the effect of the CYP3A5*3 polymorphism on everolimus hepatic metabolism in vitro.
Results

Clinical pharmacogenetics of everolimus in renal transplant patients

None of the patients were homozygous carriers of the CYP3A5*1 allele. Seven were heterozygous carriers of this allele and 21 non carriers. Patients carriers of the CYP3A5*1 active allele (i.e. expressers) and non carriers (i.e. non expressers) received similar doses of everolimus (1.6±0.9 versus 2.2±1.1 mg; p=0.2959) and had similar everolimus blood levels at all sampling times (Figure 1). The two groups had no significantly different dose-normalized exposure indices (Table 1). Corticosteroid doses and patients’ renal function at the time of blood sampling were similar in CYP3A5*1 and CYP3A5*3 allele carriers (Table 2).

In vitro metabolism of everolimus by P450

Initial experiments with recombinant CYP3A4, CYP3A5 and CYP2C8 confirmed previous findings (2) that the three P450 isoforms are able to metabolize everolimus. The relative contribution of CYP3A and CYP2C8 to everolimus hepatic metabolism estimated using the Relative Activity Factor (RAF) approach was 93% and 7%, respectively. Chemical inhibition of CYP3A4 and CYP2C8 confirmed these results: troleandomycin and trimethoprim resulted in 87.7±10.7% and 4.2±3.8% inhibition of everolimus metabolic depletion by human liver microsomes (HLM).

The metabolic intrinsic clearance (CL_{int}) of everolimus by CYP3A4 and CYP3A5 was estimated from its in vitro half-life, using tacrolimus as a positive control. The CL_{int} of everolimus was 1.7-fold lower with recombinant CYP3A5 than CYP3A4, while it was 2.7-fold higher for tacrolimus (Figure 2). The activity of both P450s was greatly enhanced when they were co-expressed with cytochrome b5. However, CYP3A5+b5 still had a lower CL_{int} than CYP3A4+b5 towards everolimus and a higher CL_{int} towards tacrolimus (Figure 2).

Metabolism of everolimus by genotyped microsomes
Among the 49 hepatic microsomal preparations, 40 (81.6%) came from homozygous carriers of \textit{CYP3A5*3} and 9 (18.4%) from heterozygotes. Pools of CYP3A5 expressing and non expressing hepatic microsomes, prepared based on the genotype, showed similar CL\textsubscript{int} for everolimus (632 [CI\textsubscript{95%} 515-748] versus 723 [CI\textsubscript{95%} 358-1088] µl/mg protein/min, respectively; p = 0.1107), while the former had a 1.75-fold higher CL\textsubscript{int} for tacrolimus, the positive control (2717 [CI\textsubscript{95%} 2401-3034] versus 1547 [CI\textsubscript{95%} 1176-1919] µl/mg protein/min; p = 0.0280).

\textbf{Discussion}

Immunosuppressants are narrow therapeutic index drugs and many of them are substrates for CYP3A enzymes. This exploratory study showed that the \textit{CYP3A5*3} polymorphism did not influence everolimus dose requirement, exposure or dose-normalized exposure in 28 stable renal transplants. Further experimental studies demonstrated that CYP3A4 is more active than CYP3A5 in everolimus metabolism and confirmed, using genotyped HLM, that the \textit{CYP3A5*3} polymorphism has no significant influence on the metabolism of everolimus. Only one former clinical study in cardiac transplants investigated the effect of the \textit{CYP3A5*3} genotype on everolimus pharmacokinetics, and no association was found either (8). The number of subjects in this previous study was quite small (n=30), as in the present one, but sample size calculation showed that it was sufficient to detect an effect similar to that observed for the parent drug sirolimus (6), with a power of 80%. In both studies, patients were not cotreated with calcineurin inhibitors which ensures that enzyme inhibition cannot have interacted with the pharmacogenetic association. A limitation of these two studies is that none of the patients studied were homozygous carriers of the \textit{CYP3A5*1} active allele, a rare genotype in patients of European ancestry. We cannot totally exclude a significantly higher metabolic clearance of everolimus in patients of this particular genotype. This should be
explored in patients of African ancestry, known to carry the \textit{CYP3A5*1} allele at much higher frequency (9).

We provide here experimental evidence that the \textit{CYP3A5*1/*3} genotype does not influence the hepatic metabolism of everolimus. In contrast, the metabolism of tacrolimus, used as positive control, was substantially higher in microsomes derived from CYP3A5 expressers, a genotype effect consistent with numerous clinical reports (3, 10-12).

We found that CYP3A4 is a better catalyst of everolimus than CYP3A5, while the opposite was observed for tacrolimus. This provides a first explanation to the fact that CYP3A5 expression does not significantly influence everolimus metabolism. CYP2C8 is the only other P450 isoform reported to be involved in the metabolism of everolimus (2). In the present study, we found that it accounts for less than 7% of everolimus overall in vitro metabolism. This excludes that this isoform can substantially contribute to everolimus metabolism and thus to its pharmacokinetic variability.

It is also noteworthy that everolimus overall metabolic clearance is 2-to-4 fold lower than that of tacrolimus, suggesting that the hepatic first-pass effect is less critical for everolimus than tacrolimus. The hepatic microsomal CL_{int} of everolimus observed here is also 2-fold lower than what we previously reported for sirolimus (677 versus 1271 µl/mg protein/min) (13). This is consistent with the knowledge that the 40-O-(2-hydroxyethyl) group on everolimus results in a 3-fold lower total CL_{int} of P450-dependent metabolism than sirolimus by inhibiting demethylation at position 39 (the major metabolism of sirolimus) and hydroxylation in the C10 to C14 region (the major hydroxylation region of sirolimus) (2). This probably explains the difference in oral bioavailability between the two drugs and suggests that everolimus would be less subject to interindividual variability in first-pass metabolism.
CYP3A5 expression does not appear to contribute substantially to everolimus pharmacokinetic variability. A potential explanation for the observed variability is the contribution of CYP3A4 and P-gp in the small intestine and the liver. It is well established that there is considerable inter-individual variation in CYP3A4 activity, but no polymorphism that would result in absence of activity has been described. SNPs giving rise to alterations in catalytic activity are seen at very low population frequencies, precluding their inclusion in the present study (14). We did not consider P-gp polymorphisms. The literature remains unclear on the precise consequences of P-gp genetic variations on drug pharmacokinetics and most studies investigating the parent drug sirolimus reported no association (5, 7, 15). Everolimus pharmacokinetic variability is likely to be explained by a combination of factors including genetics, epigenetics, gender, diets, diseases, and comedications.

In conclusion, this study provides direct and indirect lines of evidence strongly suggesting that CYP3A5 genotyping is of no clinical relevance in either kidney graft recipients on everolimus, or in candidates to receive it.

**Materials and Methods**

**Patients**

28 kidney graft recipients followed as outpatients at Toulouse Rangueil hospital were enrolled in the study. The median time from transplant to the study was 7.2 years (range: 7 months to 18.5 years). All patients received induction therapy with basiliximab or antithymocyte globulin and a standard tapered corticosteroid regimen. The patients had been administered everolimus for 3 to 44 months (median: 24 months) prior to the study. The drug was administered twice daily, targeting a whole blood trough concentration between 5 and 15 µg/l. There was no dose modification for at least 2 months before the study. Twenty-three of the twenty-eight patients received mycophenolate mofetil given at an initial fixed dose of 1g
twice daily, reduced if necessary based on clinical criteria. Blood samples were collected in each patient at 0, 20, 40, 60, 90, 120, 180, 240, 360, 540 and 720 min after the morning dose of everolimus. No drugs interacting with CYP3A or P-glycoprotein (P-gp) were allowed to be used in this study.

The study was approved by the ethics committee of Rangueil hospital and informed consent was obtained from each patient.

**Drug determination**

Everolimus whole blood determination was performed using turbulent flow chromatography-tandem mass spectrometry, as previously described for sirolimus (13). Two MS/MS transitions were monitored for everolimus (m/z 975.5 → 908.5; m/z 975.5 → 858.5) and for the internal standard desmethoxy sirolimus (m/z 901.3 → 816.4; m/z 901.3 → 834.2). The method was fully validated for everolimus determination in whole blood and adapted to in vitro incubation supernatant, as previously described for sirolimus (13). Briefly, sample preparation consisted of mixing for 15 sec 100 µl of samples with 150 µl of a mixture of methanol/aqueous zinc sulfate (70:30; v/v) and 50 µl of internal standard (100 µg/l in acetonitrile). The limit of quantitation was 0.5 µg/l and calibration curves obtained using quadratic regression from the limit of quantitation up to 100 µg/l yielded r² > 0.99.

Tacrolimus was determined by liquid chromatography-tandem mass spectrometry as previously described (16).

Everolimus area under the concentration curve (AUC0–12h) was estimated using the trapezoidal rule.

**Chemicals**

Everolimus was obtained from Novartis Pharma AG (Basel, Switzerland) and tacrolimus from Fujisawa Pharmaceuticals (Osaka, Japan). All other chemicals were purchased from Sigma-Aldrich (St-Louis, MO).
**Enzymes and human microsomes**

Recombinant CYP3A4 and 3A5 (each co-expressed with or without cytochrome \(b_5\)) and CYP2C8 (with cytochrome \(b_5\)) Supersomes® were purchased from BD Biosciences (Bedford, MA).

Human liver (n=49) tissue samples derived from surgical specimens were obtained from Biopredic International (Rennes, France). All samples were collected after donors had given their informed consent, in accordance with the French bioethics laws. Each sample was examined by a pathologist and only histologically nontumorous tissue was used. Genomic DNA was extracted from each tissue sample (13) and HLM prepared (17) as described previously.

**In vitro metabolic experiments**

The metabolism of everolimus was studied by incubating HLM (0.1-0.2 mg protein/ml) or P450 Supersomes® (10-75 pmol/ml) in 0.1 mol/l Tris-HCl, pH 7.4, with 10 mmol/l MgCl\(_2\) and 100 µg/l everolimus. Following preincubation for 5 min at 37°C, the reaction was initiated by adding 2 mmol/l NADPH. After 0, 2, 5, 10, 15, 20, 30 minutes, aliquots (50 µl) were removed from the mixture and dispensed into tubes containing 50 µl of ice-cold acetonitrile to stop the reaction. Similar experiments were performed using tacrolimus (100 µg/l) as a substrate.

Drug determination was performed as described above and the half-life of everolimus or tacrolimus metabolic depletion estimated using an exponential decay model in GraphPad Prism 5. The total in vitro CL\(_{int}\) was then estimated using the formula described by Obach et al. (18). In order to estimate the specific contribution of CYP3A and CYP2C8 to everolimus metabolism, the activity obtained with the respective recombinant P450s after 30 min of incubation was scaled to HLM using the previously described RAF approach (19). The RAF of CYP3A (0.240) and CYP2C8 (0.145) were calculated using the catalytic activities reported...
by BD Biosciences for Supersomes® and pooled human microsomes towards selective substrates (i.e., testosterone for CYP3A and paclitaxel for CYP2C8). The relative contribution of each isoform to everolimus metabolism was estimated as the ratio of individual to total P450 scaled activity. Chemical inhibition of everolimus metabolism after 30 minutes incubation with HLM was also studied using troleandomycin as CYP3A inhibitor or trimethoprim as CYP2C8 inhibitor.

Genotyping

Patients DNA was isolated from EDTA-treated blood using the Qiagen blood mini kit (Qiagen, Courtaboeuf, France) and was genotyped for the CYP3A5*3 (A6986G, rs776746) single nucleotide polymorphism using a validated TaqMan allelic discrimination assay on an ABI PRISM 7000 Sequence Detection System (Applied-Biosystems, Courtaboeuf, France).

Statistical analysis

The number of patients required for the clinical study was calculated assuming a ratio between CYP3A5 expressers and non-expressers similar to that observed in our bank of HLM from donors operated on in France (i.e. 1:4), an expected difference in everolimus dose-normalized AUC between expressers and non expressers similar to that reported for sirolimus (6), a one-sided significance of 0.05 and a statistical power of 0.8. A minimum of 5 expressers/20 non-expressers was required. Deviations of genotype frequencies from the Hardy-Weinberg equilibrium were investigated using the Fisher-exact test. Categorical variables were compared using the Fisher’s exact test and continuous variables using the non-parametric Mann-Whitney test in StatView (SAS Institute, Cary, NC, version 5.0).

Acknowledgments: We thank Biopredic International for their support.
References


Table 1: Patients exposure to everolimus according to the CYP3A5*3 genotype.

<table>
<thead>
<tr>
<th>CYP3A5 Genotypes</th>
<th>dn-C₀ (µg/l)m/mg</th>
<th>dn-C_max (µg/l)/mg</th>
<th>T_max (h)</th>
<th>dn-AUC₀-12h (µg.h/l)/mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP3A5*1/*3 (n=7)</td>
<td>3.4±2.0</td>
<td>11.6±4.6</td>
<td>1.0±0.4</td>
<td>61.1±20.3</td>
</tr>
<tr>
<td>CYP3A5*3/*3 (n=21)</td>
<td>3.8±1.8</td>
<td>13.7±5.8</td>
<td>0.7±0.2</td>
<td>69.6±29.2</td>
</tr>
</tbody>
</table>

| p values | 0.4417 | 0.4417 | 0.2125 | 0.5418 |

- 16 -
Table 2: Characteristics of the study population according to CYP3A5 genotype.

<table>
<thead>
<tr>
<th></th>
<th>CYP3A5*1/*3 (n=7)</th>
<th>CYP3A5*3/*3 (n=21)</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of recipient (years)</td>
<td>53±12</td>
<td>51±12</td>
<td>0.5926</td>
</tr>
<tr>
<td>Male sex (n; %)</td>
<td>3 (43%)</td>
<td>15 (71%)</td>
<td>0.2075</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>64±11</td>
<td>66±19</td>
<td>0.5211</td>
</tr>
<tr>
<td>Years since transplantation (range)</td>
<td>10 (0.6-19)</td>
<td>7 (1.1-18)</td>
<td>0.7908</td>
</tr>
<tr>
<td>Mycophenolate mofetil cotreatment (n; %)</td>
<td>5 (71%)</td>
<td>18 (85%)</td>
<td>0.4318</td>
</tr>
<tr>
<td>Corticosteroid dose (range)</td>
<td>2.1 mg (0-5)</td>
<td>2.5 mg (0-10)</td>
<td>0.2057</td>
</tr>
<tr>
<td>Serum creatinine levels</td>
<td>130.7 µmol/l</td>
<td>131.2 µmol/l</td>
<td>0.6863</td>
</tr>
</tbody>
</table>
Figure Legends

**Figure 1:** Mean ± SD of dose-normalized concentration-time profiles of everolimus as a function of the CYP3A5 genotype (CYP3A5*1/*3: n=7; CYP3A5*3/*3: n=21).

**Figure 2:** Estimated in vitro intrinsic clearance (CL\textsubscript{int}) of everolimus (a) and tacrolimus (b) metabolism by human recombinant cytochrome P450 (rhCYP) 3A4 and 3A5. Grayed box represents the activity of rhCYP co-expressed with cytochrome b5 and hatched box the activity of rhCYP without cytochrome b5. The CL\textsubscript{int} were estimated from tacrolimus and everolimus in vitro metabolic half-lives as described in the materials and methods section. Results are derived from duplicate experiments.
Figure 1
Figure 2